Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 387

1.

Reply to Tenover et al., "Guidelines Support the Value of Stand-Alone Nucleic Acid Amplification Tests for Clostridioides (Clostridium) difficile Infection".

Sandlund J, Wilcox MH.

J Clin Microbiol. 2019 Sep 24;57(10). pii: e01157-19. doi: 10.1128/JCM.01157-19. Print 2019 Oct. No abstract available.

PMID:
31551344
2.

Combating resistance while maintaining innovation: the future of antimicrobial stewardship.

Vickers RJ, Bassetti M, Clancy CJ, Garey KW, Greenberg DE, Nguyen MH, Roblin D, Tillotson GS, Wilcox MH.

Future Microbiol. 2019 Sep 17. doi: 10.2217/fmb-2019-0227. [Epub ahead of print]

3.

Investigating the transient and persistent effects of heat on Clostridium difficile spores.

Pickering DS, Vernon JJ, Freeman J, Wilcox MH, Chilton CH.

J Med Microbiol. 2019 Oct;68(10):1445-1454. doi: 10.1099/jmm.0.001048. Epub 2019 Aug 8.

4.

Influence of Diagnostic Method on Outcomes in Phase 3 Clinical Trials of Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infection: A Post Hoc Analysis of MODIFY I/II.

Wilcox MH, Rahav G, Dubberke ER, Gabryelski L, Davies K, Berry C, Eves K, Ellison MC, Guris D, Dorr MB.

Open Forum Infect Dis. 2019 Aug 1;6(8). pii: ofz293. doi: 10.1093/ofid/ofz293.

5.

A two-step approach for the investigation of a Clostridium difficile outbreak by molecular methods.

Krutova M, Wilcox MH, Kuijper EJ.

Clin Microbiol Infect. 2019 Jul 29. pii: S1198-743X(19)30414-8. doi: 10.1016/j.cmi.2019.07.022. [Epub ahead of print] No abstract available.

PMID:
31369805
6.

The perils of PCR-based diagnosis of Clostridioides difficile infections: Painful lessons from clinical trials.

Kong LY, Davies K, Wilcox MH.

Anaerobe. 2019 Jun 12. pii: S1075-9964(19)30098-8. doi: 10.1016/j.anaerobe.2019.06.001. [Epub ahead of print]

PMID:
31201853
7.

Valuing antibiotics: The role of the hospital clinician.

Masterton RG, Bassetti M, Chastre J, MacDonald AG, Rello J, Seaton RA, Welte T, Wilcox MH, West P.

Int J Antimicrob Agents. 2019 Jul;54(1):16-22. doi: 10.1016/j.ijantimicag.2019.05.012. Epub 2019 May 11.

PMID:
31085298
8.

Cross-sectional study of the prevalence, causes and management of hospital-onset diarrhoea.

Mawer D, Byrne F, Drake S, Brown C, Prescott A, Warne B, Bousfield R, Skittrall JP, Ramsay I, Somasunderam D, Bevan M, Coslett J, Rao J, Stanley P, Kennedy A, Dobson R, Long S, Obisanya T, Esmailji T, Petridou C, Saeed K, Brechany K, Davis-Blue K, O'Horan H, Wake B, Martin J, Featherstone J, Hall C, Allen J, Johnson G, Hornigold C, Amir N, Henderson K, McClements C, Liew I, Deshpande A, Vink E, Trigg D, Guilfoyle J, Scarborough M, Scarborough C, Wong THN, Walker T, Fawcett N, Morris G, Tomlin K, Grix C, O'Cofaigh E, McCaffrey D, Cooper M, Corbett K, French K, Harper S, Hayward C, Reid M, Whatley V, Winfield J, Hoque S, Kelly L, King I, Bradley A, McCullagh B, Hibberd C, Merron M, McCabe C, Horridge S, Taylor J, Koo S, Elsanousi F, Saunders R, Lim F, Bond A, Stone S, Milligan ID, Mack DJF, Nagar A, West RM, Wilcox MH, Kirby A, Sandoe JAT.

J Hosp Infect. 2019 Oct;103(2):200-209. doi: 10.1016/j.jhin.2019.05.001. Epub 2019 May 8.

PMID:
31077777
9.

Service evaluation of alcohol-release door plates: an addition to hand hygiene.

Wilcox MH, Dyche A.

J Hosp Infect. 2019 Sep;103(1):e97-e100. doi: 10.1016/j.jhin.2019.04.023. Epub 2019 May 7.

PMID:
31071383
10.

Clostridium difficile trehalose metabolism variants are common and not associated with adverse patient outcomes when variably present in the same lineage.

Eyre DW, Didelot X, Buckley AM, Freeman J, Moura IB, Crook DW, Peto TEA, Walker AS, Wilcox MH, Dingle KE.

EBioMedicine. 2019 May;43:347-355. doi: 10.1016/j.ebiom.2019.04.038. Epub 2019 Apr 27.

11.

A Review of Mixed Strain Clostridium difficile Colonization and Infection.

Dayananda P, Wilcox MH.

Front Microbiol. 2019 Apr 10;10:692. doi: 10.3389/fmicb.2019.00692. eCollection 2019. Review.

12.

'The method used to dry washed hands affects the number and type of transient and residential bacteria remaining on the skin'.

Redway K, Barbut F, Wilcox MH.

J Hosp Infect. 2019 Aug;102(4):473-474. doi: 10.1016/j.jhin.2019.04.006. Epub 2019 Apr 13. No abstract available.

PMID:
30991082
13.

Dissemination of multiple carbapenem resistance genes in an in vitro gut model simulating the human colon.

Rooney CM, Sheppard AE, Clark E, Davies K, Hubbard ATM, Sebra R, Crook DW, Walker AS, Wilcox MH, Chilton CH.

J Antimicrob Chemother. 2019 Jul 1;74(7):1876-1883. doi: 10.1093/jac/dkz106.

PMID:
30989197
14.

Efficacy and Safety of Tedizolid Phosphate versus Linezolid in a Randomized Phase 3 Trial in Patients with Acute Bacterial Skin and Skin Structure Infection.

Lv X, Alder J, Li L, O'Riordan W, Rybak MJ, Ye H, Zhang R, Zhang Z, Zhu X, Wilcox MH.

Antimicrob Agents Chemother. 2019 Jun 24;63(7). pii: e02252-18. doi: 10.1128/AAC.02252-18. Print 2019 Jul.

15.

Ultrasensitive Detection of Clostridium difficile Toxins Reveals Suboptimal Accuracy of Toxin Gene Cycle Thresholds for Toxin Predictions.

Sandlund J, Wilcox MH.

J Clin Microbiol. 2019 May 24;57(6). pii: e01885-18. doi: 10.1128/JCM.01885-18. Print 2019 Jun.

16.

A Role for Tetracycline Selection in Recent Evolution of Agriculture-Associated Clostridium difficile PCR Ribotype 078.

Dingle KE, Didelot X, Quan TP, Eyre DW, Stoesser N, Marwick CA, Coia J, Brown D, Buchanan S, Ijaz UZ, Goswami C, Douce G, Fawley WN, Wilcox MH, Peto TEA, Walker AS, Crook DW.

MBio. 2019 Mar 12;10(2). pii: e02790-18. doi: 10.1128/mBio.02790-18.

17.

Ceftaroline fosamil therapy in patients with acute bacterial skin and skin-structure infections with systemic inflammatory signs: A retrospective dose comparison across three pivotal trials.

Corey GR, Wilcox MH, Gonzalez J, Jandourek A, Wilson DJ, Friedland HD, Das S, Iaconis J, Dryden M.

Int J Antimicrob Agents. 2019 Jun;53(6):830-837. doi: 10.1016/j.ijantimicag.2019.01.016. Epub 2019 Feb 1.

18.

Corrigendum to "Environmental contamination by bacteria in hospital washrooms according to hand-drying method: a multi-centre study" [J Hospital Infection 100 (2018) 469-475].

Best E, Parnell P, Couturier J, Barbut F, Le Bozec A, Arnoldo L, Madia A, Brusaferro S, Wilcox MH.

J Hosp Infect. 2019 Apr;101(4):487. doi: 10.1016/j.jhin.2019.01.014. Epub 2019 Jan 31. No abstract available.

19.

Cadazolid for the treatment of Clostridium difficile infection: results of two double-blind, placebo-controlled, non-inferiority, randomised phase 3 trials.

Gerding DN, Cornely OA, Grill S, Kracker H, Marrast AC, Nord CE, Talbot GH, Buitrago M, Gheorghe Diaconescu I, Murta de Oliveira C, Preotescu L, Pullman J, Louie TJ, Wilcox MH.

Lancet Infect Dis. 2019 Mar;19(3):265-274. doi: 10.1016/S1473-3099(18)30614-5. Epub 2019 Jan 29.

20.

Molecular epidemiology of Clostridioides (previously Clostridium) difficile isolates from a university hospital in Minas Gerais, Brazil.

Diniz AN, de Oliveira Júnior CA, Vilela EG, Figueiredo HCP, Rupnik M, Wilcox MH, Fawley WN, Blanc DS, Faria Lobato FC, Silva ROS.

Anaerobe. 2019 Apr;56:34-39. doi: 10.1016/j.anaerobe.2019.01.010. Epub 2019 Jan 29.

PMID:
30703440
21.

Effect of fluoroquinolone resistance mutation Thr-82→Ile on Clostridioides difficile fitness.

Vernon JJ, Wilcox MH, Freeman J.

J Antimicrob Chemother. 2019 Apr 1;74(4):877-884. doi: 10.1093/jac/dky535.

PMID:
30590496
22.

The predictive value of quantitative nucleic acid amplification detection of Clostridium difficile toxin gene for faecal sample toxin status and patient outcome.

Davies KA, Planche T, Wilcox MH.

PLoS One. 2018 Dec 5;13(12):e0205941. doi: 10.1371/journal.pone.0205941. eCollection 2018.

23.

Management of complicated skin and soft tissue infections with a special focus on the role of newer antibiotics.

Leong HN, Kurup A, Tan MY, Kwa ALH, Liau KH, Wilcox MH.

Infect Drug Resist. 2018 Oct 25;11:1959-1974. doi: 10.2147/IDR.S172366. eCollection 2018. Review.

24.

Omadacycline Gut Microbiome Exposure Does Not Induce Clostridium difficile Proliferation or Toxin Production in a Model That Simulates the Proximal, Medial, and Distal Human Colon.

Moura IB, Buckley AM, Ewin D, Shearman S, Clark E, Wilcox MH, Chilton CH.

Antimicrob Agents Chemother. 2019 Jan 29;63(2). pii: e01581-18. doi: 10.1128/AAC.01581-18. Print 2019 Feb.

25.

Comparison of the 2010 and 2017 Infectious Diseases Society of America guidelines on the diagnosis and treatment of Clostridium difficile infection.

Wilcox MH, Rooney CM.

Curr Opin Gastroenterol. 2019 Jan;35(1):20-24. doi: 10.1097/MOG.0000000000000489.

PMID:
30394898
26.

Irritable bowel syndrome following Clostridium difficile infection.

Dayananda P, Wilcox MH.

Curr Opin Gastroenterol. 2019 Jan;35(1):1-5. doi: 10.1097/MOG.0000000000000490.

PMID:
30335629
27.

Biofilm-derived spores of Clostridioides (Clostridium) difficile exhibit increased thermotolerance compared to planktonic spores.

Pickering DS, Wilcox MH, Chilton CH.

Anaerobe. 2018 Dec;54:169-171. doi: 10.1016/j.anaerobe.2018.10.003. Epub 2018 Oct 5.

28.

Surveillance of iclaprim activity: in vitro susceptibility of Gram-positive skin infection pathogens collected from 2015 to 2016 from North America and Europe.

Huang DB, Magnet S, De Angelis S, Holland TL, File TM Jr, Dryden M, Corey GR, Torres A, Wilcox MH.

Diagn Microbiol Infect Dis. 2019 Feb;93(2):154-158. doi: 10.1016/j.diagmicrobio.2018.09.002. Epub 2018 Sep 10.

29.

Bezlotoxumab for Clostridium difficile Infection Complicating Inflammatory Bowel Disease.

Kelly CP, Wilcox MH, Glerup H, Aboo N, Ellison MC, Eves K, Dorr MB.

Gastroenterology. 2018 Oct;155(4):1270-1271. doi: 10.1053/j.gastro.2018.06.080. Epub 2018 Sep 15. No abstract available.

30.

Trends over time in Escherichia coli bloodstream infections, urinary tract infections, and antibiotic susceptibilities in Oxfordshire, UK, 1998-2016: a study of electronic health records.

Vihta KD, Stoesser N, Llewelyn MJ, Quan TP, Davies T, Fawcett NJ, Dunn L, Jeffery K, Butler CC, Hayward G, Andersson M, Morgan M, Oakley S, Mason A, Hopkins S, Wyllie DH, Crook DW, Wilcox MH, Johnson AP, Peto TEA, Walker AS.

Lancet Infect Dis. 2018 Oct;18(10):1138-1149. doi: 10.1016/S1473-3099(18)30353-0. Epub 2018 Aug 17.

31.

Comparative efficacy of treatments for Clostridium difficile infection: a systematic review and network meta-analysis.

Beinortas T, Burr NE, Wilcox MH, Subramanian V.

Lancet Infect Dis. 2018 Sep;18(9):1035-1044. doi: 10.1016/S1473-3099(18)30285-8. Epub 2018 Jul 17.

32.

Correlation between restriction endonuclease analysis and PCR ribotyping for the identification of Clostridioides (Clostridium) difficile clinical strains.

Kociolek LK, Perdue ER, Fawley WN, Wilcox MH, Gerding DN, Johnson S.

Anaerobe. 2018 Dec;54:1-7. doi: 10.1016/j.anaerobe.2018.07.004. Epub 2018 Aug 3.

33.

Environmental contamination by bacteria in hospital washrooms according to hand-drying method: a multi-centre study.

Best E, Parnell P, Couturier J, Barbut F, Le Bozec A, Arnoldo L, Madia A, Brusaferro S, Wilcox MH.

J Hosp Infect. 2018 Dec;100(4):469-475. doi: 10.1016/j.jhin.2018.07.002. Epub 2018 Jul 10. Erratum in: J Hosp Infect. 2019 Apr;101(4):487.

34.

Real-Life Evidence for Tedizolid Phosphate in the Treatment of Cellulitis and Wound Infections: A Case Series.

Shlyapnikov S, Jauregui A, Khachatryan NN, Kurup A, de la Cabada-Bauche J, Leong HN, Li L, Wilcox MH.

Infect Dis Ther. 2018 Sep;7(3):387-399. doi: 10.1007/s40121-018-0207-0. Epub 2018 Jul 12.

35.

Clostridium difficile: Investigating Transmission Patterns Between Infected and Colonized Patients Using Whole Genome Sequencing.

Kong LY, Eyre DW, Corbeil J, Raymond F, Walker AS, Wilcox MH, Crook DW, Michaud S, Toye B, Frost E, Dendukuri N, Schiller I, Bourgault AM, Dascal A, Oughton M, Longtin Y, Poirier L, Brassard P, Turgeon N, Gilca R, Loo VG.

Clin Infect Dis. 2019 Jan 7;68(2):204-209. doi: 10.1093/cid/ciy457.

36.

Impact of Clostridium difficile toxin gene PCR result on decisions to de-isolate patients: Do the ends justify the means?

Morris KA, Davies K, Wilcox MH.

J Infect Prev. 2018 May;19(3):138-140. doi: 10.1177/1757177418755309. Epub 2018 Feb 16.

37.

Pooled analysis of the phase 3 REVIVE trials: randomised, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin-structure infections.

Huang DB, Corey GR, Holland TL, Lodise T, O'Riordan W, Wilcox MH, File TM Jr, Dryden M, Balser B, Desplats E, Torres A.

Int J Antimicrob Agents. 2018 Aug;52(2):233-240. doi: 10.1016/j.ijantimicag.2018.05.012. Epub 2018 May 19.

38.

Patient and Strain Characteristics Associated With Clostridium difficile Transmission and Adverse Outcomes.

Martin JSH, Eyre DW, Fawley WN, Griffiths D, Davies K, Mawer DPC, Peto TEA, Crook DW, Walker AS, Wilcox MH.

Clin Infect Dis. 2018 Oct 15;67(9):1379-1387. doi: 10.1093/cid/ciy302.

39.

Two Distinct Patterns of Clostridium difficile Diversity Across Europe Indicating Contrasting Routes of Spread.

Eyre DW, Davies KA, Davis G, Fawley WN, Dingle KE, De Maio N, Karas A, Crook DW, Peto TEA, Walker AS, Wilcox MH; EUCLID Study Group.

Clin Infect Dis. 2018 Sep 14;67(7):1035-1044. doi: 10.1093/cid/ciy252.

40.

Reply to Joseph et al.

Wilcox MH.

J Hosp Infect. 2018 Aug;99(4):434-435. doi: 10.1016/j.jhin.2018.03.026. Epub 2018 Mar 27. No abstract available.

41.

Towards precision medicine in sepsis: a position paper from the European Society of Clinical Microbiology and Infectious Diseases.

Rello J, van Engelen TSR, Alp E, Calandra T, Cattoir V, Kern WV, Netea MG, Nseir S, Opal SM, van de Veerdonk FL, Wilcox MH, Wiersinga WJ.

Clin Microbiol Infect. 2018 Dec;24(12):1264-1272. doi: 10.1016/j.cmi.2018.03.011. Epub 2018 Mar 24.

PMID:
29581049
42.

Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA).

McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, Dubberke ER, Garey KW, Gould CV, Kelly C, Loo V, Shaklee Sammons J, Sandora TJ, Wilcox MH.

Clin Infect Dis. 2018 Mar 19;66(7):987-994. doi: 10.1093/cid/ciy149.

PMID:
29562266
43.

Understanding Clostridium difficile Colonization.

Crobach MJT, Vernon JJ, Loo VG, Kong LY, Péchiné S, Wilcox MH, Kuijper EJ.

Clin Microbiol Rev. 2018 Mar 14;31(2). pii: e00021-17. doi: 10.1128/CMR.00021-17. Print 2018 Apr. Review.

44.

A Phase 3, Randomized, Double-Blind, Multicenter Study To Evaluate the Safety and Efficacy of Intravenous Iclaprim versus Vancomycin for Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed To Be Due to Gram-Positive Pathogens (REVIVE-2 Study).

Holland TL, O'Riordan W, McManus A, Shin E, Borghei A, File TM Jr, Wilcox MH, Torres A, Dryden M, Lodise T, Oguri T, Corey GR, McLeroth P, Shukla R, Huang DB.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e02580-17. doi: 10.1128/AAC.02580-17. Print 2018 May.

45.

The pitfalls of laboratory diagnostics of Clostridium difficile infection.

Krutova M, Wilcox MH, Kuijper EJ.

Clin Microbiol Infect. 2018 Jul;24(7):682-683. doi: 10.1016/j.cmi.2018.02.026. Epub 2018 Mar 2. Review. No abstract available.

46.

Guidance document for prevention of Clostridium difficile infection in acute healthcare settings.

Tschudin-Sutter S, Kuijper EJ, Durovic A, Vehreschild MJGT, Barbut F, Eckert C, Fitzpatrick F, Hell M, Norèn T, O'Driscoll J, Coia J, Gastmeier P, von Müller L, Wilcox MH, Widmer AF; Committee.

Clin Microbiol Infect. 2018 Oct;24(10):1051-1054. doi: 10.1016/j.cmi.2018.02.020. Epub 2018 Mar 2. Review.

47.

Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA).

McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, Dubberke ER, Garey KW, Gould CV, Kelly C, Loo V, Shaklee Sammons J, Sandora TJ, Wilcox MH.

Clin Infect Dis. 2018 Mar 19;66(7):e1-e48. doi: 10.1093/cid/cix1085.

48.

Investigating the effect of supplementation on Clostridioides (Clostridium) difficile spore recovery in two solid agars.

Pickering DS, Vernon JJ, Freeman J, Wilcox MH, Chilton CH.

Anaerobe. 2018 Apr;50:38-43. doi: 10.1016/j.anaerobe.2018.01.010. Epub 2018 Feb 1.

49.

European Practice for CDI Treatment.

Fitzpatrick F, Skally M, Brady M, Burns K, Rooney C, Wilcox MH.

Adv Exp Med Biol. 2018;1050:117-135. doi: 10.1007/978-3-319-72799-8_8. Review.

PMID:
29383667
50.

Surveillance of iclaprim activity: In vitro susceptibility of gram-positive pathogens collected from 2012 to 2014 from the United States, Asia Pacific, Latin American and Europe.

Huang DB, File TM Jr, Dryden M, Corey GR, Torres A, Wilcox MH.

Diagn Microbiol Infect Dis. 2018 Apr;90(4):329-334. doi: 10.1016/j.diagmicrobio.2017.12.001. Epub 2017 Dec 7.

Supplemental Content

Loading ...
Support Center